


## NS3861

Cat. No.:	HY-110121A
CAS No.:	216853-59-7
Molecular Formula:	C <sub>12</sub> H <sub>14</sub> BrNS
Molecular Weight:	284.22
Target:	nAChR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (175.92 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	3.5184 mL	17.5920 mL	35.1840 mL
				5 mM	0.7037 mL	3.5184 mL	7.0368 mL
				10 mM	0.3518 mL	1.7592 mL	3.5184 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.80 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.80 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (8.80 mM); Clear solution						

### BIOLOGICAL ACTIVITY

Description	NS3861 is an agonist of nicotinic acetylcholine receptors (nAChRs) and binds with high affinity to heteromeric α3β4 nAChR. The binding K <sub>i</sub> values of 0.62, 25, 7.8, 55 nM for α3β4, α3β2, α4β4, α4β2, respectively <sup>[1]</sup> .
In Vitro	NS3861 displays the opposite β-subunit preference and a complete lack of activation at α4-containing receptors in HEK293 cell lines. NS3861 selectively activates α3- but not α4-containing nAChRs and it displays higher efficacy at the α3β2 receptor compared with the α3β4 receptor, with EC <sub>50</sub> s of 1.7 and 0.15 μM for α3β2 and α3β4 receptor, respectively <sup>[1]</sup> . NS3861 shows high affinity and partial agonist properties in α3β4-expressed nAChRs <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Kasper Harpsøe, et al. Molecular determinants of subtype-selective efficacies of cytisine and the novel compound NS3861 at heteromeric nicotinic acetylcholine receptors. *J Biol Chem.* 2013 Jan 25;288(4):2559-70.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA